Plasma gabapentin concentrations in children with epilepsy: Influence of age, relationship with dosage, and preliminary observations on correlation with clinical response

被引:28
作者
Gatti, G
Ferrari, AR
Guerrini, R
Bonanni, P
Bonomi, I
Perucca, E
机构
[1] Univ Pavia, Clin Pharmacol Unit, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] Univ Pisa, Inst Child Neurol & Psychiat, Pisa, Italy
[3] IRCSS Stella Maris Fdn, Pisa, Italy
关键词
gabapentin; pharmacokinetics; epilepsy; children; therapeutic drug monitoring;
D O I
10.1097/00007691-200302000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
The influence of age and administered daily dosage on the plasma concentrations of gabapentin (GBP) at steady state was evaluated in a group of 41 children and young adults (aged 3-30 years) receiving long-term adjunctive treatment with GBP for the management of refractory partial-onset seizures. For each patient, peak and trough concentrations were determined by a specific high-performance liquid chromatography (HPLC) method in samples obtained before the morning dose and 2.5 hours later, respectively. To assess within-subject relationship between plasma concentration and dosage, 30 patients were evaluated at more than one dosage level. Within the assessed dose range, plasma GBP concentrations were linearly related to dose. Apparent oral clearance values (mean +/- SD) in children aged 6 years or less (4.8 +/- 0.9 mL/kg/min) were comparable with those observed in children aged 7 to 15 years (4.6 + 1.5 mL/kg/min) and moderately higher than those found in young adults (3.9 + 0.9 mL/kg/min), even though differences among groups failed to reach statistical significance. There was, however, a significant difference in CL/F between children aged 10 years or less and older children (5.1 +/- 1.1 vs. 3.8 +/- 1.2 mL/kg/min, P < 0.005). Of the 41 patients who entered the study, 22 discontinued treatment, mostly due to insufficient efficacy. No significant difference in plasma GBP concentration was detected between patients showing a greater than 50% reduction in seizure frequency (4.1 +/- 1.9 mug/mL, n = 11, mean SD) and those having no significant clinical improvement (4.4 +/- 1.7 mug/mL, n = 30). These results indicate that in children given dosages up to 50 mg/kg/d (mean, 25 mg/kg/d), GBP pharmacokinetic analyses show no important deviation from linearity. The data also suggest that, on average, children may need moderately higher dosages to reach plasma GBP concentrations comparable with those found in adults. There seems to be a large variation in the plasma concentrations of the drug associated with a favorable therapeutic response.
引用
收藏
页码:54 / 60
页数:7
相关论文
共 21 条
[1]
Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial [J].
Backonja, M ;
Beydoun, A ;
Edwards, KR ;
Schwartz, SL ;
Fonseca, V ;
Hes, M ;
LaMoreaux, L ;
Garofalo, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21) :1831-1836
[2]
Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy [J].
Beydoun, A ;
Fakhoury, T ;
Nasreddine, W ;
Abou-Khalil, B .
EPILEPSIA, 1998, 39 (02) :188-193
[3]
Effects of age and gender on single-dose pharmacokinetics of gabapentin [J].
Boyd, RA ;
Türck, D ;
Abel, RB ;
Sedman, TJ ;
Bockbrader, HN .
EPILEPSIA, 1999, 40 (04) :474-479
[4]
GABAPENTIN - A REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND CLINICAL POTENTIAL IN EPILEPSY [J].
GOA, KL ;
SORKIN, EM .
DRUGS, 1993, 46 (03) :409-427
[5]
Single-dose gabapentin pharmacokinetics and safety in healthy infants and children [J].
Haig, GM ;
Bockbrader, HN ;
Wesche, DL ;
Boellner, SW ;
Ouellet, D ;
Brown, RR ;
Randinitis, EJ ;
Posvar, EL .
JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (05) :507-514
[6]
Efficacy of gabapentin therapy in children with refractory partial seizures [J].
Khurana, DS ;
Riviello, J ;
Helmers, S ;
Holmes, G ;
Anderson, J ;
Mikati, MA .
JOURNAL OF PEDIATRICS, 1996, 128 (06) :829-833
[7]
LENSMEYER GL, 1995, THER DRUG MONIT, V17, P251
[8]
Nonepileptic uses of gabapentin [J].
Magnus, L .
EPILEPSIA, 1999, 40 :S66-S72
[9]
MARSON AG, 2000, COCHRANE DATABASE SY
[10]
Mirza WU, 1999, EPILEPSIA, V40, P145